Published in Vaccines (Basel) on April 23, 2015
A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma | NCT01970358
Vaccine-based immunotherapeutic approaches to gliomas and beyond. Nat Rev Neurol (2017) 0.77
In Vivo Expansion of Melanoma-Specific T Cells Using Microneedle Arrays Coated with Immune-Polyelectrolyte Multilayers. ACS Biomater Sci Eng (2016) 0.75
Whole cell vaccination using immunogenic cell death by an oncolytic adenovirus is effective against a colorectal cancer model. Mol Ther Oncolytics (2016) 0.75
Polyelectrolyte-Enrobed Cancer Cells in View of Personalized Immune-Therapy. Adv Sci (Weinh) (2017) 0.75
Enhancing the treatment effect on melanoma by heat shock protein 70-peptide complexes purified from human melanoma cell lines. Oncol Rep (2016) 0.75
Advancing Cancer Therapy with Present and Emerging Immuno-Oncology Approaches. Front Oncol (2017) 0.75
Safety of targeting tumor endothelial cell antigens. J Transl Med (2016) 0.75
Cancer Vaccines in Ovarian Cancer: How Can We Improve? Biomedicines (2016) 0.75
The novel immunomodulator IMMUNEPOTENT CRP combined with chemotherapy agent increased the rate of immunogenic cell death and prevented melanoma growth. Oncol Lett (2017) 0.75
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
Genes expressed in human tumor endothelium. Science (2000) 10.75
Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2006) 10.54
Molecular identification of a danger signal that alerts the immune system to dying cells. Nature (2003) 8.90
Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol (2007) 8.33
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76
Exploring the genomes of cancer cells: progress and promise. Science (2011) 6.16
A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature (2000) 6.12
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med (2013) 6.01
Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med (2009) 5.79
Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med (2000) 5.62
Malignant effusions and immunogenic tumour-derived exosomes. Lancet (2002) 4.91
TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell (2005) 4.46
Exploiting the mutanome for tumor vaccination. Cancer Res (2012) 4.45
Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res (2001) 3.29
Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol (1986) 3.29
Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst (2013) 3.07
Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. Cancer Res (2007) 3.07
Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med (2002) 3.02
Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A (1990) 2.91
The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol (2006) 2.90
Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer Res (2005) 2.72
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res (2007) 2.71
Induction of myeloid-derived suppressor cells by tumor exosomes. Int J Cancer (2009) 2.64
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol (2013) 2.64
Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res (2003) 2.62
Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res (1999) 2.55
Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol (2008) 2.53
Development of dendritic-cell lineages. Immunity (2007) 2.53
Shortage of circulating naive CD8(+) T cells provides new insights on immunodeficiency in aging. Blood (2000) 2.46
Proteomic analysis of melanoma-derived exosomes by two-dimensional polyacrylamide gel electrophoresis and mass spectrometry. Proteomics (2004) 2.43
Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann N Y Acad Sci (2003) 2.36
The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A (2005) 2.22
Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J Immunol (2007) 2.16
Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells. Blood (2008) 2.12
TEM8 interacts with the cleaved C5 domain of collagen alpha 3(VI). Cancer Res (2004) 2.07
Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci U S A (1998) 2.05
Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol Ther (2008) 2.00
Hsp70 translocates into the plasma membrane after stress and is released into the extracellular environment in a membrane-associated form that activates macrophages. J Immunol (2008) 1.95
Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol (2001) 1.81
The cancer antigenome. EMBO J (2012) 1.78
Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. J Clin Oncol (2005) 1.75
Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res (2007) 1.71
Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol (1995) 1.71
Intradermal immunization improves protective efficacy of a novel TB vaccine candidate. Vaccine (2009) 1.58
The long pentraxin PTX3 binds to apoptotic cells and regulates their clearance by antigen-presenting dendritic cells. Blood (2000) 1.58
Dissection of T-cell antigen specificity in human melanoma. Cancer Res (2012) 1.52
Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer. Clin Cancer Res (2006) 1.50
Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res (2005) 1.48
Antigens for cancer immunotherapy. Semin Immunol (2008) 1.46
Heat shock protein 70, released from heat-stressed tumor cells, initiates antitumor immunity by inducing tumor cell chemokine production and activating dendritic cells via TLR4 pathway. J Immunol (2009) 1.44
Hepatitis B vaccines: WHO position paper--recommendations. Vaccine (2009) 1.44
Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther (2006) 1.43
Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol (2002) 1.38
Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res (2010) 1.38
Dendritic cells resurrect antigens from dead cells. Trends Immunol (2001) 1.35
Dendritic cell derived-exosomes: biology and clinical implementations. J Leukoc Biol (2006) 1.34
Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol (1999) 1.29
More efficient induction of HLA-A*0201-restricted and carcinoembryonic antigen (CEA)-specific CTL response by immunization with exosomes prepared from heat-stressed CEA-positive tumor cells. Clin Cancer Res (2005) 1.29
Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells. J Clin Oncol (2009) 1.27
Alternative routes of measles immunization: a review. Biologicals (1997) 1.27
Uric acid promotes tumor immune rejection. Cancer Res (2004) 1.26
Adaptive vaccination strategies to mitigate pandemic influenza: Mexico as a case study. PLoS One (2009) 1.24
Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro Oncol (2006) 1.23
Contrasting effects of TGF-beta 1 and TNF-alpha on the development of dendritic cells from progenitors in mouse bone marrow. Stem Cells (1997) 1.21
Whole tumor antigen vaccines. Semin Immunol (2010) 1.19
In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma. J Immunother (2007) 1.18
Soluble plasma HLA peptidome as a potential source for cancer biomarkers. Proc Natl Acad Sci U S A (2010) 1.18
IL-7 gene therapy in aging restores early thymopoiesis without reversing involution. J Immunol (2004) 1.16
GM-CSF gene-transduced tumor vaccines. Mol Ther (2005) 1.16
Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer. Mol Ther (2011) 1.15
Immunity, ageing and cancer. Immun Ageing (2008) 1.13
Antitumor immune responses induced by ionizing irradiation and further immune stimulation. Cancer Immunol Immunother (2013) 1.13
p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Proc Natl Acad Sci U S A (1996) 1.11
Complexity of dendritic cell subsets and their function in the host immune system. Immunology (2011) 1.11
Age-associated alterations in the recruitment of signal-transduction proteins to lipid rafts in human T lymphocytes. J Leukoc Biol (2003) 1.10
Intradermal hepatitis B virus vaccine: immunogenicity and side-effects in adults. Lancet (1984) 1.10
Hyperthermia as an immunotherapy strategy for cancer. Curr Opin Investig Drugs (2009) 1.09
Effects of cis-9, trans-11 and trans-10, cis-12 conjugated linoleic acid (CLA) isomers on immune function in healthy men. Eur J Clin Nutr (2003) 1.09
Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther (2006) 1.08
Seprase promotes rapid tumor growth and increased microvessel density in a mouse model of human breast cancer. Cancer Res (2004) 1.08
Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol Immunother (2013) 1.08
Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis. Cancer Res (2000) 1.06
Tumor stroma as targets for cancer therapy. Pharmacol Ther (2012) 1.06
Enhancement of natural killer (NK) cell cytotoxicity by fever-range thermal stress is dependent on NKG2D function and is associated with plasma membrane NKG2D clustering and increased expression of MICA on target cells. J Leukoc Biol (2007) 1.05
Angiogenesis and the tumor vasculature as antitumor immune modulators: the role of vascular endothelial growth factor and endothelin. Curr Top Microbiol Immunol (2011) 1.05
Extracellular targeting of endoplasmic reticulum chaperone glucose-regulated protein 170 enhances tumor immunity to a poorly immunogenic melanoma. J Immunol (2006) 1.05
Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA. Eur J Immunol (2005) 1.05
Hyperthermia enhances CTL cross-priming. J Immunol (2006) 1.05
Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: experience in 81 patients. Ann Oncol (2000) 1.01
A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clin Cancer Res (2013) 1.01
Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines. Int Rev Immunol (2011) 1.01
Whole tumor antigen vaccination using dendritic cells: comparison of RNA electroporation and pulsing with UV-irradiated tumor cells. J Transl Med (2008) 1.00
Age-associated decline in effective immune synapse formation of CD4(+) T cells is reversed by vitamin E supplementation. J Immunol (2007) 0.99
Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings. Mol Ther (2004) 0.97
Increased expression of seprase, a membrane-type serine protease, is associated with lymph node metastasis in human colorectal cancer. Cancer Lett (2003) 0.96
The expression of a type II transmembrane serine protease (Seprase) in human gastric carcinoma. Oncology (2004) 0.96
Hypochlorous acid enhances immunogenicity and uptake of allogeneic ovarian tumor cells by dendritic cells to cross-prime tumor-specific T cells. Cancer Immunol Immunother (2006) 0.96